Tag - SNGX

Markets

Dawson James cuts Soligenix to neutral; PT to $2 from $3

Dawson James Securities downgraded Soligenix (NASDAQ:SNGX) to “neutral” from “buy” and reduced its price target to $2 from $3, citing a model update for dilution. The stock closed at $2.13 on July 27. “We have updated...

July 28, 2020

Developments

Soligenix reports positive second cycle results from Phase 3 cutaneous T-cell lymphoma trial

Soligenix (NASDAQ:SNGX) reported positive second cycle results for its Phase 3 trial assessing SGX301 for the treatment of cutaneous T-cell lymphoma (CTCL). The study enrolled 169 patients who were randomized to receive...

April 30, 2020

Developments

Soligenix reports positive topline results from Phase 3 cutaneous T-cell lymphoma trial

Soligenix (NASDAQ:SNGX) reported positive topline results for its Phase 3 trial assessing SGX301 for the treatment of cutaneous T-cell lymphoma (CTCL). The study enrolled 169 patients who were randomized to receive...

March 19, 2020

Developments

Soligenix gets fast track designation for RiVax

The FDA granted fast track designation to Soligenix’s (NASDAQ:SNGX) RiVax for the prevention of ricin intoxication. Ricin is a lethal plant-derived toxin whose stability and high potency make it a potential biological...

February 13, 2020

Tag - SNGX

Dawson James cuts Soligenix to neutral; PT to $2 from $3

Soligenix reports positive second cycle results from Phase 3 cutaneous T-cell lymphoma trial

Soligenix reports positive topline results from Phase 3 cutaneous T-cell lymphoma trial

Soligenix gets fast track designation for RiVax

General

More